Centre for Genomic Regulation (CRG)’s Post

A new study showcases that concurrent tissue-based and ctDNA-based genomic profiling identifies more targetable variants than tissue-based testing alone. Among 3.209 patients with non–small cell lung cancer, breast cancer, prostate cancer, or colorectal cancer, 9.3% had actionable biomarkers detected only via ctDNA profiling. Especially breast cancer patients benefitted from ctDNA profiling, as most of the variants were detected in the ESR1 gene. Access the study: https://lnkd.in/eNU_PR-S We recognize the potential of integrating simultaneous tissue and ctDNA testing to improve patient outcomes. #molecularprofiling #ctDNA #cancer 

As the treatment landscape for HR-positive, HER2-negative metastatic breast cancer evolves, comprehensive genomic profiling for ESR1 mutations and PI3K/AKT pathway genomic alterations can help with monitoring for acquired resistance and aid with therapy decisions. Our new study in Breast Cancer Research and Treatment examines real-world, de-identified data from Foundation Medicine to assess the prevalence of these mutations at the start of successive lines of treatment and explores the role tissue and liquid biopsies play in monitoring for acquired genomic alterations across lines of therapy while also highlighting the important role of tumor fraction in providing confidence in accurately interpreting liquid biopsy results. To learn more about the findings from this #research, check out the link here: https://bit.ly/4bbRTYN #BreastCancer #GenomicProfiling

🔈Research news 🔬 New research reveals a key vulnerability in LKB1-deficient non-small cell lung cancer (NSCLC), which is one of the deadliest forms of cancer and affects about 30% of cases all patients suffering from NSCLC. With contributions from professor Jiri Bartek, head of the Genome Integrity Group at the Danish Cancer Institute, a team of international scientists used zebrafish and human lung organoid models to screen for compounds that target these tumours. They identified two kinase inhibitors, Piceatannol and Tyrphostin 23, that show promise for more effective treatments. #cancer #cancerresearch #science #lungcancer

Moderna is taking a multipronged approach in #oncology with investigational #mRNA candidates targeting multiple cancer types. One such approach is our investigational individualized neoantigen therapy, which we are developing in collaboration with Merck, and is being investigated in skin, lung, bladder, and kidney cancer. Every person and every tumor is one-of-a-kind, arising from a unique set of evolving tumor mutations. With an improved understanding of cancer biology and immunology, the scientific community is making great strides toward accounting for this uniqueness and tailoring treatment to the makeup of a patient’s cancer. #AACR24

Very exciting developments in #oncology from Moderna! Our innovative work on individualized neoantigen therapy, in partnership with Merck, targets the uniqueness of each patient's cancer, promising personalized treatments for skin, lung, bladder, and kidney cancers. This approach represents a leap forward in leveraging mRNA technology to fight cancer, highlighting the importance of personalized medicine. Proud to see such strides being made toward understanding and treating the complexity of cancer. #AACR24

Access the widely used MB49 murine bladder carcinoma cell line on CancerTools.org (CancerToolsOrg). This line is one of the most established in vitro and in vivo models of urothelial bladder cancer with metastatic potential. It shares pivotal characteristics with human bladder cancer and has been widely used for more than 45 years after its original publication by Cancer Research UK (CRUK) researcher, Leonard Franks. Our MB49 derivatives include #MB49-luc cell line, offering an in vivo readout for tumour take, growth, and reduction.  Click here to access the MB49 cell lines: https://hubs.la/Q02vgph-0 #lifesciences #mb49 #celllines #oncologyresearch #mousebladder #carcinoma #cancerresearch #genomics #researchtools #bladdercancer #depositedbyscientists #acceleratecancerresearch

In an intriguing exploration at the intersection of virology and oncology, early mouse studies suggest that the Zika virus could hold promise in treating cancer. The research delves into the Zika virus's ability to target and destroy glioblastoma stem cells, a particularly aggressive form of brain cancer, without causing harm to normal brain cells. While in the nascent stages, this study unveils a novel avenue for potential cancer therapies, showcasing the diverse applications of viral research in the quest for innovative treatments. Learn more: https://bit.ly/48uHHZT #CancerResearch #AnimalResearch #LaboratoryAnimalSciences #ResearchWednesday

#Researchers, mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) are among the most common oncogenic driver mutations found in human cancers. The KRAS G12C mutation is present in about 12% of patients with non-small-cell lung cancer, 4% of patients with colorectal cancer and 1% of patients with pancreatic ductal adenocarcinoma. BI-0474 is a novel, irreversible covalent inhibitor of KRAS G12C, developed in collaboration with Alex Waterson, Jason Phan, Andrew Little, Jason Abbott, Sune Qi, and Steven Fesik Vanderbilt School of Medicine Basic Sciences. Get it now for free on #opnMe and explore new research avenues https://lnkd.in/eQmYtHRQ #OpenScience #Boehringer

Check out our latest publication in Cells focusing on our scientists' research on colon cancer. Discover how potential biomarker candidates are being identified and the impact of the tumor microenvironment in colorectal cancer. https://okt.to/ueypz1

#Researchers, mutations in the Kirsten rat sarcoma viral protein (KRAS) are commonly found in human cancers. The KRAS G12C mutation is present in about 12% of patients with non-small-cell lung cancer, 4% of patients with colorectal cancer and 1% of patients with pancreatic ductal adenocarcinoma. BI-0474 is a novel, irreversible inhibitor of KRAS G12C, developed in collaboration with Vanderbilt University. Get it now for free on our open science portal #opnMe and explore new research avenues: https://lnkd.in/egjsKJkR